BACKGROUND: The management of patients with colorectal cancer (CRC) with peritoneal metastases is challenging, and the roles of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are unclear and debated among experts. MATERIALS AND METHODS: The experts of the Swiss Peritoneal Cancer Group were contacted and agreed to participate in this analysis. Experts from 9 centers in Switzerland provided their decision algorithms for CRS/HIPEC for patients with or at high risk for peritoneal metastases from CRC. Their responses were converted into decision trees on the basis of objective consensus methodology. The decision trees were used as a basis to identify consensus and discrepancies. RESULTS: The final treatment a...
International audienceWhen peritoneal metastases are diagnosed (strong agreement of experts): (i) se...
Peritoneal carcinomatosis (PC) is a difficult clinical challenge in colorectal cancer (CRC) because ...
Up to 25% of patients with metastatic colorectal cancer (CRC) present with peritoneal carcinomatosis...
BACKGROUND: The management of patients with colorectal cancer (CRC) with peritoneal metastases is ch...
BACKGROUND The management of patients with colorectal cancer (CRC) with peritoneal metastases is ...
Background: Peritoneal cancer index (PCI) >20 is often seen as a contraindication for cytoreducti...
BACKGROUND: At present, selected patients with resectable colorectal peritoneal metastases (CRC-PM)...
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal car...
International audienceBackground: The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) ...
The peritoneal cavity is a common site of metastatic spread from colorectal cancer (CRC). Patients w...
PURPOSE Colorectal cancer (CRC) has potential to spread within the peritoneal cavity, and this tr...
Background: Advanced colorectal cancer (CRC) is prone to developing peritoneal carcinomatosis (PC). ...
BACKGROUND:Peritoneal carcinomatosis (PC) is a difficult clinical challenge in colorectal cancer (CR...
Background Up to 15 per cent of colorectal cancers present with peritoneal metastases (CPM). Cyto...
International audienceWhen peritoneal metastases are diagnosed (strong agreement of experts): (i) se...
Peritoneal carcinomatosis (PC) is a difficult clinical challenge in colorectal cancer (CRC) because ...
Up to 25% of patients with metastatic colorectal cancer (CRC) present with peritoneal carcinomatosis...
BACKGROUND: The management of patients with colorectal cancer (CRC) with peritoneal metastases is ch...
BACKGROUND The management of patients with colorectal cancer (CRC) with peritoneal metastases is ...
Background: Peritoneal cancer index (PCI) >20 is often seen as a contraindication for cytoreducti...
BACKGROUND: At present, selected patients with resectable colorectal peritoneal metastases (CRC-PM)...
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal car...
International audienceBackground: The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) ...
The peritoneal cavity is a common site of metastatic spread from colorectal cancer (CRC). Patients w...
PURPOSE Colorectal cancer (CRC) has potential to spread within the peritoneal cavity, and this tr...
Background: Advanced colorectal cancer (CRC) is prone to developing peritoneal carcinomatosis (PC). ...
BACKGROUND:Peritoneal carcinomatosis (PC) is a difficult clinical challenge in colorectal cancer (CR...
Background Up to 15 per cent of colorectal cancers present with peritoneal metastases (CPM). Cyto...
International audienceWhen peritoneal metastases are diagnosed (strong agreement of experts): (i) se...
Peritoneal carcinomatosis (PC) is a difficult clinical challenge in colorectal cancer (CRC) because ...
Up to 25% of patients with metastatic colorectal cancer (CRC) present with peritoneal carcinomatosis...